Drug Profile
Research programme: anti-apoptosis inhibitor of macrophages antibodies - Sumitomo Pharma/Trans Genic
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma; Trans Genic; University of Tokyo
- Developer Sumitomo Pharma; University of Tokyo
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic syndrome